Candriam S.C.A. Sells 875 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Candriam S.C.A. reduced its stake in Medpace Holdings, Inc. by 1.4%, owning 60,317 shares valued at approximately $18.4 million after selling 875 shares in the first quarter.
• Barclays PLC increased its position in Medpace by 42.4%, while other institutional investors also adjusted their stakes, indicating significant interest in the company.
• Medpace reported $3.10 earnings per share, exceeding expectations, with revenue of $603.31 million, marking a 14.2% increase compared to the previous year.

Candriam S.C.A. trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 1.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,317 shares of the company's stock after selling 875 shares during the quarter. Candriam S.C.A. owned about 0.21% of Medpace worth $18,378,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Brooklyn Investment Group boosted its stake in shares of Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after purchasing an additional 71 shares during the period. Whittier Trust Co. raised its holdings in Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after purchasing an additional 35 shares in the last quarter. Colonial Trust Co SC raised its holdings in Medpace by 150.0% during the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after purchasing an additional 105 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Medpace during the first quarter worth approximately $60,000. Finally, Assetmark Inc. increased its holdings in shares of Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after acquiring an additional 43 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 3,000 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the transaction, the general counsel directly owned 10,343 shares of the company's stock, valued at approximately $4,654,350. This trade represents a 22.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Jesse J. Geiger sold 41,801 shares of Medpace stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $453.11, for a total value of $18,940,451.11. Following the transaction, the president directly owned 36,503 shares in the company, valued at approximately $16,539,874.33. The trade was a 53.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 114,450 shares of company stock valued at $51,791,251. 20.30% of the stock is owned by corporate insiders.

Medpace Stock Up 2.3%

Shares of Medpace stock traded up $10.30 on Friday, hitting $463.64. 328,935 shares of the company's stock traded hands, compared to its average volume of 424,882. The stock has a market cap of $13.02 billion, a P/E ratio of 34.47, a PEG ratio of 2.92 and a beta of 1.42. The firm's 50-day moving average is $378.86 and its 200 day moving average is $335.05. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same period in the prior year, the company posted $2.75 EPS. The business's revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of recent research reports. Barclays lifted their target price on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. William Blair restated a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Finally, TD Cowen reissued a "sell" rating and issued a $366.00 target price (up previously from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, Medpace currently has a consensus rating of "Reduce" and an average price target of $406.60.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.